Stock Comparison

LLY vs NUVB

Eli Lilly and Co vs Nuvation Bio Inc

The Verdict

NUVB takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

NUVB

Nuvation Bio Inc

8.7

out of 10

Hidden Gem

Head-to-Head

$965.0B

Market Cap

$1.6B

52.6

P/E Ratio

-7.7

N/A

Profit Margin

-325.3%

N/A

Return on Equity

0.0%

N/A

Debt-to-Equity

0.2

Moderate

Overall Risk

Aggressive

0.5

DVR Score

8.7

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

NUVB8.7/10

Nuvation Bio (NUVB) sustains its high 10x growth potential, reflecting robust progress in its transformation to a commercial-stage oncology firm. The Q4 2025 revenue beat and initial IBTROZI® product revenue of $24.7M with 216 new patient starts validate its commercial launch. Furthermore, the EMA's validation of taletrectinib's marketing application and upcoming pivotal data presentation at AACR ...

Full NUVB Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.